{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:13:00Z","timestamp":1790709180586,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12850-5","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T03:15:40Z","timestamp":1770952540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Epidemiological characteristics, genotype patterns, and treatment outcomes in chronic hepatitis C patients receiving direct-acting antivirals: a cohort study from Istanbul, T\u00fcrkiye"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2791-4957","authenticated-orcid":false,"given":"Semra","family":"Karaman Kamal\u0131","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevtap","family":"Senoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sercan","family":"Kamal\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf Emre","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadriye","family":"Kart Yasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"issue":"10407","key":"12850_CR1","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(23)01320-X","volume":"402","author":"M Martinello","year":"2023","unstructured":"Martinello M, Solomon SS, Terrault NA, Dore GJ. Hepat C Lancet. 2023;402(10407):1085\u201396.","journal-title":"Hepat C Lancet"},{"issue":"3","key":"12850_CR2","doi-asserted-by":"publisher","first-page":"101626","DOI":"10.1016\/j.clinre.2021.101626","volume":"45","author":"S Roger","year":"2021","unstructured":"Roger S, Ducancelle A, Le Guillou-Guillemette H, Gaudy C, Lunel F. HCV virology and diagnosis. Clin Res Hepatol Gastroenterol. 2021;45(3):101626.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"12850_CR3","unstructured":"Hepatitis C. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c. Accessed 19-07-2025."},{"issue":"11","key":"12850_CR4","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.cmi.2015.06.028","volume":"21","author":"N Tozun","year":"2015","unstructured":"Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21(11):1020\u20136.","journal-title":"Clin Microbiol Infect"},{"key":"12850_CR5","unstructured":"Epidemiology and transmission of hepatitis C virus infection - UpToDate. [Accessed 30-12-2023]. Available from: https:\/\/www.uptodate.com\/contents\/epidemiology-and-transmission-of-hepatitis-c-virus-infection"},{"issue":"2","key":"12850_CR6","first-page":"172","volume":"7","author":"L Kuna","year":"2019","unstructured":"Kuna L, Jakab J, Smolic R, Wu GY, Smolic M. HCV extrahepatic manifestations. J Clin Transl Hepatol. 2019;7(2):172\u201382.","journal-title":"J Clin Transl Hepatol"},{"key":"12850_CR7","unstructured":"Shawa IT, Hepatitis B. and C viruses. Hepatitis B and C. Intech open. 2019 Mar 1."},{"issue":"4","key":"12850_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/jvh.13646","volume":"29","author":"AJ Stockdale","year":"2022","unstructured":"Stockdale AJ, Kreuels B, Shawa IT, Meiring JE, Thindwa D, Silungwe NM, et al. A clinical and molecular epidemiological survey of hepatitis C in Blantyre, Malawi, suggests a historic mechanism of transmission. J Viral Hepat. 2022;29(4):252\u201362.","journal-title":"J Viral Hepat"},{"key":"12850_CR9","unstructured":"Sosyal G\u00fcvenlik Kurumu Ba\u015fkanl\u0131\u011f\u0131ndan: SOSYAL G\u00dcVENL\u0130K KURUMU SA\u011eLIK UYGULAMA TEBL\u0130\u011e\u0130NDE DE\u011e\u0130\u015e\u0130KL\u0130K YAPILMASINA DA\u0130R TEBL\u0130\u011e. [Accessed 28-12-2023]. Available from: https:\/\/www.resmigazete.gov.tr\/eskiler\/2018\/12\/20181228M1-1.pdf"},{"issue":"2","key":"12850_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.5152\/tjg.2020.18798","volume":"31","author":"A \u00c7etin Duran","year":"2020","unstructured":"\u00c7etin Duran A, Kaya \u00c7etinkaya \u00d6, Say\u0131ner AA, \u015eeydao\u011flu G, \u00d6zkarata\u015f E, Abac\u0131o\u011flu H. Changes on hepatitis C virus genotype distribution in Western turkey: evaluation of twelve-year data. Turk J Gastroenterol. 2020;31(2):128\u201335.","journal-title":"Turk J Gastroenterol"},{"issue":"1","key":"12850_CR11","first-page":"86","volume":"55","author":"ME Bulut","year":"2021","unstructured":"Bulut ME, Topalca US, Murat A, Teke L, Canalp HZ, Ocal M, Bayraktar B. HCV genotype distribution of patients with chronic hepatitis C in Istanbul. Sisli Etfal Hastan Tip Bul. 2021;55(1):86\u201392.","journal-title":"Sisli Etfal Hastan Tip Bul"},{"key":"12850_CR12","doi-asserted-by":"crossref","unstructured":"Kulah C, Altindis M, Akyar I, Gokahmetoglu S, Sayiner A, Kaleli I, et al. The prevalence of mixed genotype infections in Turkish patients with hepatitis C: a multicentered assessment. Clin Lab. 2019;65(4).","DOI":"10.7754\/Clin.Lab.2018.180824"},{"issue":"11","key":"12850_CR13","doi-asserted-by":"publisher","first-page":"971","DOI":"10.5152\/tjg.2022.21834","volume":"33","author":"F Sar\u0131g\u00fcl Y\u0131ld\u0131r\u0131m","year":"2022","unstructured":"Sar\u0131g\u00fcl Y\u0131ld\u0131r\u0131m F, \u00dcser \u00dc, Sar\u0131 ND, Kurtaran B, \u00d6nlen Y, \u015eenate\u015f E, et al. In a Real-Life Setting, Direct-Acting antivirals to people who inject drugs with chronic hepatitis C in Turkey. Turk J Gastroenterol. 2022;33(11):971\u20138.","journal-title":"Turk J Gastroenterol"},{"issue":"41","key":"12850_CR14","doi-asserted-by":"publisher","first-page":"11567","DOI":"10.3748\/wjg.v21.i41.11567","volume":"21","author":"Y Lurie","year":"2015","unstructured":"Lurie Y, Webb M, Cytter-Kuint R, Shteingart S, Lederkremer GZ. Noninvasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol. 2015;21(41):11567\u201383.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"12850_CR15","first-page":"92","volume":"8","author":"NM Hawsawi","year":"2023","unstructured":"Hawsawi NM, Saber T, Salama HM, Fouad WS, Hagag HM, Alhuthali HM, et al. Genotypes of hepatitis C virus and efficacy of Direct-Acting antiviral drugs among chronic hepatitis C patients in a tertiary care hospital. Trop Med Infect Dis. 2023;8(2):92.","journal-title":"Trop Med Infect Dis"},{"issue":"10","key":"12850_CR16","doi-asserted-by":"publisher","first-page":"862","DOI":"10.5152\/tjg.2022.21271","volume":"33","author":"Y \u00d6nlen","year":"2022","unstructured":"\u00d6nlen Y, Bal T, \u00c7abalak M, \u00c7uvalc\u0131 \u00d6ztoprak N, Sar\u0131 ND, Kurtaran B, et al. Efficacy and safety of Direct-Acting antivirals in elderly patients with chronic hepatitis C: A nationwide Real-Life, Observational, multicenter study from Turkey. Turk J Gastroenterol. 2022;33(10):862\u201373.","journal-title":"Turk J Gastroenterol"},{"issue":"4","key":"12850_CR17","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3904\/kjim.2022.252","volume":"38","author":"J Heo","year":"2023","unstructured":"Heo J, Kim YJ, Lee SW, Lee YJ, Yoon KT, Soo Byun K, et al. Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in korea: a phase 3b study. Korean J Intern Med. 2023;38(4):504\u201313.","journal-title":"Korean J Intern Med"},{"issue":"1","key":"12850_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12879-018-3148-z","volume":"18","author":"DJ Ruzicka","year":"2018","unstructured":"Ruzicka DJ, Tetsuka J, Fujimoto G, Kanto T. Comorbidities and comedications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016. BMC Infect Dis. 2018;18(1):237.","journal-title":"BMC Infect Dis"},{"issue":"8","key":"12850_CR19","doi-asserted-by":"publisher","first-page":"e0196908","DOI":"10.1371\/journal.pone.0196908","volume":"13","author":"DM Evon","year":"2018","unstructured":"Evon DM, Stewart PW, Amador J, Serper M, Lok AS, Sterling RK, et al. A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: results from a large US multicenter observational study. PLoS ONE. 2018;13(8):e0196908.","journal-title":"PLoS ONE"},{"issue":"18","key":"12850_CR20","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.3748\/wjg.v25.i18.2229","volume":"25","author":"N Loo","year":"2019","unstructured":"Loo N, Lawitz E, Alkhouri N, Wells J, Landaverde C, Coste A, et al. Ombitasvir\/paritaprevir\/ritonavir\u2009+\u2009dasabuvir +\/- ribavirin in real world hepatitis C patients. World J Gastroenterol. 2019;25(18):2229\u201339.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"12850_CR21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s41999-019-00167-3","volume":"10","author":"M El Kassas","year":"2019","unstructured":"El Kassas M, El Sheemy R, Alboraie M, El Badry M, Wifi MN, Youssef N, et al. Real-world results of direct-acting antivirals use for the treatment of chronic hepatitis C in old patients. Eur Geriatr Med. 2019;10(2):295\u2013302.","journal-title":"Eur Geriatr Med"},{"issue":"4","key":"12850_CR22","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/hep.26387","volume":"58","author":"S Larney","year":"2013","unstructured":"Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais D, Des, Hagan H, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology. 2013;58(4):1215\u201324.","journal-title":"Hepatology"},{"key":"12850_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.drugpo.2018.06.017","volume":"59","author":"E Pontali","year":"2018","unstructured":"Pontali E, Fiore V, Ialungo AM, Ranieri R, Mollaretti O, Barbarini G, et al. Treatment with direct-acting antivirals in a multicenter cohort of HCV-infected inmates in Italy. Int J Drug Policy. 2018;59:50\u20133.","journal-title":"Int J Drug Policy"},{"issue":"Suppl 5","key":"12850_CR24","doi-asserted-by":"publisher","first-page":"S392","DOI":"10.1093\/infdis\/jiaa142","volume":"222","author":"D Winetsky","year":"2020","unstructured":"Winetsky D, Burack D, Antoniou P, Garcia B, Gordon P, Scherer M. Psychosocial factors and the care cascade for hepatitis C treatment colocated at a syringe service program. J Infect Dis. 2020;222(Suppl 5):S392\u2013400.","journal-title":"J Infect Dis"},{"issue":"1","key":"12850_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3906\/sag-1411-169","volume":"46","author":"E \u00dc\u00e7bilek","year":"2016","unstructured":"\u00dc\u00e7bilek E, Abayli B, Koyuncu MB, Midikli D, G\u00f6z\u00fck\u00fc\u00e7\u00fck S, Akda\u011f A, et al. Distribution of hepatitis C virus genotypes among intravenous drug users in the \u00c7ukurova region of Turkey. Turk J Med Sci. 2016;46(1):66\u201371.","journal-title":"Turk J Med Sci"},{"issue":"7","key":"12850_CR26","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","volume":"150","author":"PJ Pockros","year":"2016","unstructured":"Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, et al. Efficacy of Direct-Acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or End-Stage renal disease. Gastroenterology. 2016;150(7):1590\u20138.","journal-title":"Gastroenterology"},{"issue":"5","key":"12850_CR27","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/liv.14320","volume":"40","author":"E Lawitz","year":"2020","unstructured":"Lawitz E, Flisiak R, Abunimeh M, Sise ME, Park JY, Kaskas M, et al. Efficacy and safety of glecaprevir\/pibrentasvir in renally impaired patients with chronic HCV infection. Liver Int. 2020;40(5):1032\u201341.","journal-title":"Liver Int"},{"issue":"9","key":"12850_CR28","doi-asserted-by":"publisher","first-page":"e40357","DOI":"10.5812\/hepatmon.40357","volume":"16","author":"H Ghaderi-Zefrehi","year":"2016","unstructured":"Ghaderi-Zefrehi H, Gholami-Fesharaki M, Sharafi H, Sadeghi F, Alavian SM. The distribution of hepatitis C virus genotypes in middle Eastern countries: A systematic review and Meta-Analysis. Hepat Mon. 2016;16(9):e40357.","journal-title":"Hepat Mon"},{"issue":"44","key":"12850_CR29","doi-asserted-by":"publisher","first-page":"6551","DOI":"10.3748\/wjg.v25.i44.6551","volume":"25","author":"Y Yang","year":"2019","unstructured":"Yang Y, Wu FP, Wang WJ, Shi JJ, Li YP, Zhang X, et al. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in Northwest China. World J Gastroenterol. 2019;25(44):6551\u201360.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"12850_CR30","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/hep.27310","volume":"60","author":"B Jacka","year":"2014","unstructured":"Jacka B, Applegate T, Krajden M, Olmstead A, Harrigan PR, Marshall B, et al. Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada. Hepatology. 2014;60(5):1571\u201380.","journal-title":"Hepatology"},{"issue":"8","key":"12850_CR31","doi-asserted-by":"publisher","first-page":"e0266216","DOI":"10.1371\/journal.pone.0266216","volume":"17","author":"TJ Stopka","year":"2022","unstructured":"Stopka TJ, Yaghi O, Li M, Paintsil E, Chui K, Landy D, et al. Molecular and Spatial epidemiology of HCV among people who inject drugs in Boston, Massachusetts. PLoS ONE. 2022;17(8):e0266216.","journal-title":"PLoS ONE"},{"issue":"3","key":"12850_CR32","doi-asserted-by":"publisher","first-page":"258","DOI":"10.14218\/JCTH.2018.00014","volume":"6","author":"T Huynh","year":"2018","unstructured":"Huynh T, Zhang J, Hu KQ, Hepatitis C. Virus clearance by Direct-acting antiviral results in rapid resolution of hepatocytic injury as indicated by both Alanine aminotransferase and aspartate aminotransferase normalization. J Clin Transl Hepatol. 2018;6(3):258\u201363.","journal-title":"J Clin Transl Hepatol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12850-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12850-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12850-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:09:18Z","timestamp":1774282158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12850-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12850"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12850-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by Health Sciences University, Bakirkoy Dr. Sadi Konuk Training and Research Hospital Clinical Research Ethics Committee (Decision No: 2023-05-03, Decision Date: 06.03.2023). The requirement for individual informed consent was waived by the Bakirkoy Dr. Sadi Konuk Training and Research Hospital Ethics Committee because of the retrospective nature of the study. All procedures in this research were carried out in accordance with the ethical standards of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"603"}}